RSS Feeds
Perspectives in the Treatment of Breast Cancer: 1976
- ROBERT C. YOUNG, M.D., F.A.C.P.;
- MARC LIPPMAN, M.D.;
- VINCENT T. DEVITA, M.D., F.A.C.P.;
- JOAN BULL, M.D.; and
- DOUGLASS TORMEY, M.D., Ph.D.
Abstract
Breast cancer is the major cancer killer of women in the United States. Recent advances in therapy promise more effective control of this illness. The development of hormone receptor analysis permits us to better understand the mechanisms of action of steroid and peptide hormones and increases the likelihood of using these hormonal agents effectively. Prospective surgical and surgical adjuvant trials offer the opportunity to define accurately the appropriate surgical procedure and most effective postoperative therapy after initial surgery. The development of chemotherapy, first singly and now in combination, has led to improved treatment of patients with advanced disease and defined better chemotherapy for use in adjuvant settings. The investigation of a matrix of marker substances in breast cancer may uncover new methods to assess residual disease and to monitor disease recurrence.
Article and Author Information
-
▸An edited transcription of a Combined Clinical Staff Conference at the Clinical Center, Bethesda, Maryland, 4 March 1976, by the Medicine Branch, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, U.S. Department of Health, Education, and Welfare.
-
▸Authors who wish to cite a section of this conference and specifically indicate its author can use this example for the form of reference:
LIPPMAN M: Hormonal responsiveness of human breast cancer, pp. 784-786 in YOUNG RC (moderator): Perspectives in the Treatment of Breast Cancer: 1976. Ann Intern Med 86:784-798, 1977
-
The MCF-7 cell line (12) was provided by Dr. Marvin Rich of the Michigan Cancer Foundation; Evsa-T and Evsa-E were established and propagated as described in the text (15); MDA-231, HT-39, and G-11 were provided by Dr. Ronald Herberman of the National Cancer Institute; and ZR75-1 was established and provided by Nathaniel Young and Linda Engel of the National Cancer Institute.
-
▸Requests for reprints should be addressed to Robert C. Young, M.D.; Chief, Medicine Branch, National Cancer Institute, Bldg. 10, Rm. 12N-236, National Institutes of Health; Bethesda, MD 20014.
-
- Received January 21, 1977.
- Accepted February 10, 1977.
